Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Clare Ling has been made an honorary Fellow of the Royal College of Pathologists (FRCPath). Currently running Shoklo Malaria Research Unit (SMRU) Microbiology department and supporting the unit’s molecular activities, Clare is a clinical scientist who has worked at SMRU on the Thai-Myanmar border since 2012.

Claire Ling wearing a lab coat in her office © 2020 MORU. Photographer: Gerhard Jørén.

News of Clare’s prestigious FRCPath award was enthusiastically received by colleagues.

“Congratulations to Clare on this richly deserved accolade. She is an extraordinarily talented scientist who has made a huge impact on microbiology at SMRU, benefitting both clinical science and the large population served by the SMRU clinics,” said Prof Nick Day, Director of the MORU Tropical Health Network. “Being awarded an honorary FRCPath is a rare occurrence, and reflects the esteem that Clare is held in by her colleagues in the MORU Network and around the world.”

“This is very good news (a rarity these days) and a very well-deserved recognition!” said SMRU Director Prof François Nosten. “Under Clare’s leadership, the microbiology lab has expanded, discovered new pathogens in the population, supported the TB program and become a key partner of the Thailand Ministry of Public Health in the fight against COVID-19.”

Since joining SMRU, Clare has particularly enjoyed the synergy between humanitarian and research activities. She is invested in improving the quality of the laboratory procedures for both research and diagnostic purposes at SMRU and leads the laboratory safety committee. In addition to providing Microbiology support across the research themes (TB, MCH and malaria elimination), Clare is particularly interested in respiratory infections with ongoing collaborative projects on Mycobacterium tuberculosis, M. amphoriforme, Ornithobacterium hominis and Streptococcus pneumoniae. Clare is also working with the Community Engagement team, FilmAid and colleagues at MORU to increase the awareness of Melioidosis on the Thailand-Myanmar border and to determine if it is a rare or undiagnosed infection in the region.

Following her honours degree in Medical Microbiology at Edinburgh University, Clare completed a three-year Clinical Scientist training programme at Raigmore Hospital Inverness. During this time, she obtained an MSc in Molecular Medical Microbiology at Nottingham University and carried out research on Borrelia burgdorferi, the aetiological agent of Lyme disease. She was a member of the team involved in the isolation of B. burgdorferi for from ticks in the Highlands of Scotland, the first time this had been achieved. 

Clare then moved to the Royal Free Hospital NHS Trust, London (RFH) where she ran the molecular diagnostic service; undertook at PhD investigating a recently discovered Mycoplasma spp. Mycoplasma amphoriforme with University College London (UCL) and played an active role in the training of other scientists. Clare’s last post before joining SMRU was with Public Health England, where she pursued the development and implementation of molecular methods for gastrointestinal and respiratory infections. 

Similar stories

New report highlights growing concern of vaccine falsification

MORU OCGHR

The Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.

Indonesia’s decision to prioritise COVID-19 vaccination to citizens aged 18-59 years old questionable

EOCRU MORU OUCRU

The Indonesian government policy to exclude the elderly in the first phase of the COVID-19 vaccination program could hinder the vaccine’s impact in lowering mortality rates. COVID-19 mortality rates in Indonesia, the highest in Southeast Asia, are dominated by those in the 60 years and above age bracket. In this article published in The Conversation, Kartika Saraswati and fellow DPhil students elaborate how, by prioritising vaccination for elderly, Indonesia may optimally reduce the hospital burden and COVID-19 deaths amidst a limited vaccine supply during the first vaccination phase.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

MORU OCGHR Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

Susie Dunachie awarded flagship NIHR career development award

Awards & Appointments OCGHR

Susie Dunachie joins a prestigious group of leading health researchers in the latest cohort of NIHR Global Research Professors. These awards fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. Research conducted by Global Research Professors directly benefits people in LMICs. A Consultant in Infectious Diseases and Medical Microbiology, Susie works on the development of a vaccine to prevent death from melioidosis in people with type 2 diabetes mellitus in LMICs, and supports vaccine research in Thailand. Congratulations!

The COVID-19 vaccine: do we know enough to end the pandemic?

MORU OCGHR

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.

New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria

MORU OCGHR Publication Research

A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.